The company's device will reduce the need for some skin cancer biopsies.
Medvision Development LTD.Medivision (EuroNM: MEDVMCTC) (50%) announced today the results of a preliminary clinical trial conducted at the Beilinson Medical Center and Haemek hospital, to test the efficacy of its device for diagnosing melanomas or skin cancer. The company said it the results of the trial confirmed the scope of the technological potential for its device, although the trial was too limited to enable any final conclusions. Medvision is controlled by Micromedic Technologies Ltd. (formerly Afek Systems) (TASE:MCTC) which has a 50% share in the company.
Commenting on the trial results, Micromedic chairman David Solomon noted that millions of people worldwide were at risk of contacting melanomas. Diagnosis following presentation of acute symptoms would be too late to prevent death in 80% - 90% of cases. For this reason, doctors were exercising stringent criteria and referring many people for unnecessary biopsies, 90% of which produced negative results. Medvision’s testing device is expected to reduce the need for some of the expensive and invasive biopsy procedures.
The company has filed an application with the US Food and Drug Administration (FDA) for approval of the new product, which Solomon believes will be on the market by the end of 2006.
Published by Globes [online], Israel business news - www.globes.co.il - on February 21, 2006